Generic Secuado Availability
Last updated on Apr 10, 2025.
Secuado is a brand name of asenapine, approved by the FDA in the following formulation(s):
SECUADO (asenapine - system;transdermal)
-
Manufacturer: HISAMITSU
Approval date: October 11, 2019
Strength(s): 3.8MG/24HR [RLD], 5.7MG/24HR [RLD], 7.6MG/24HR [RLD]
Is there a generic version of Secuado available?
No. There is currently no therapeutically equivalent version of Secuado available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Secuado. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Patch
Patent 10,022,445
Issued: July 17, 2018
Inventor(s): Sonobe Atsushi & Yasukochi Takashi & Takada Yasunori
Assignee(s): HISAMITSU PHARMACEUTICAL CO., INC.In a patch comprising a support layer and an adhesive agent layer, the adhesive agent layer comprises free asenapine, a maleic acid alkali salt, and a rubber-based adhesive agent.
Patent expiration dates:
- July 25, 2033✓
- July 25, 2033
-
Patch
Patent 10,583,121
Issued: March 10, 2020
Inventor(s): Suzuki Masayuki & Okutsu Hiroaki & Yasukochi Takashi & Takada Yasunori
Assignee(s): HISAMITSU PHARMACEUTICAL CO., INC.A patch for administering asenapine includes a support layer, and an adhesive agent layer formed on the support layer and including an adhesive base agent and asenapine and/or a pharmaceutically acceptable salt thereof. The adhesive base agent has a content in a range of 10 to 90% by mass in the adhesive agent layer and includes a natural rubber, polyisobutylene, an alkyl vinyl ether(co)polymer, polyisoprene, polybutadiene, a styrene-butadiene copolymer, a styrene-isoprene copolymer, a styrene-isoprene-styrene block copolymer, or a combination thereof. When a content of the asenapine and/or pharmaceutically acceptable salt thereof in terms of free asenapine in the adhesive agent layer is 3.4 mg, an AUCfor a period starting from the time when the patch is brought into contact with a skin for 24 hours is 27,000 pg·hr/mL or more, and an AUCof an asenapine metabolite is 20% or less of the AUCof the free asenapine.
Patent expiration dates:
- July 25, 2033✓✓
- July 25, 2033
-
Patch and method for producing the same
Patent 10,814,002
Issued: October 27, 2020
Inventor(s): Suzuki Masayuki & Okutsu Hiroaki & Yasukochi Takashi & Takada Yasunori
Assignee(s): HISAMITSU PHARMACEUTICAL CO., INC.A method for producing a patch including a support layer, and an adhesive agent layer formed on the support layer and including sodium diacetate, a pressure-sensitive adhesive base agent, and asenapine and/or a pharmaceutically acceptable salt thereof. The sodium diacetate is generated from sodium acetate in the presence of the asenapine and/or salt thereof, a content of the asenapine and/or salt thereof in terms of free asenapine in the adhesive agent layer is in range of 3.0 to 20 mg, and when a content of the asenapine and/or salt thereof in terms of free asenapine in the adhesive agent layer is 6.4 mg and the patch is in contact with skin for 24 hours, Cof free asenapine is in range of 0.5 to 6.0 ng/mL and tof free asenapine is in range of 8 to 28 hr.
Patent expiration dates:
- July 25, 2033✓✓
- July 25, 2033
-
Patch
Patent 11,123,305
Issued: September 21, 2021
Inventor(s): Sonobe Atsushi & Yasukochi Takashi & Takada Yasunori
Assignee(s): HISAMITSU PHARMACEUTICAL CO., INC.In a patch comprising a support layer and an adhesive agent layer, the adhesive agent layer comprises free asenapine, a maleic acid alkali salt, and a rubber-based adhesive agent.
Patent expiration dates:
- July 25, 2033✓
- July 25, 2033
-
Patch
Patent 11,813,364
Issued: November 14, 2023
Inventor(s): Sonobe; Atsushi et al.
Assignee(s): HISAMITSU PHARMACEUTICAL CO., INC. (Tosu, JP)In a patch comprising a support layer and an adhesive agent layer, the adhesive agent layer comprises free asenapine, a maleic acid alkali salt, and a rubber-based adhesive agent.
Patent expiration dates:
- September 22, 2033✓
- September 22, 2033
-
Patch
Patent 9,687,474
Issued: June 27, 2017
Inventor(s): Suzuki Masayuki & Okutsu Hiroaki & Yasukochi Takashi & Takada Yasunori
Assignee(s): HISAMITSU PHARMACEUTICAL CO., INC.In a patch comprising a support layer and an adhesive agent layer, the adhesive agent layer comprises asenapine and/or a pharmaceutically acceptable salt thereof, isopropyl palmitate, and an adhesive base agent.
Patent expiration dates:
- July 25, 2033✓
- July 25, 2033
More about Secuado (asenapine)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (1)
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: atypical antipsychotics
- Breastfeeding
- En español
Patient resources
Other brands
Professional resources
Other brands
Related treatment guides
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.